INFECTIOUS EXACERBATION OF BRONCHIECTASIS SUCCESSFULLY TREATED WITH CEFTRIAXONE/SULBACTAM/DISODIUM EDETATE-1034 (ELORES™)


Parag Sharma

Abstract


ABSTRACT
Bronchiectasis is a type of chronic obstructive pulmonary disease, defined as permanent abnormal dilation of bronchi due to vicious cycle of transmural
infection and inflammation. Bronchiectasis is generally characterized by cough, wheeze, and dyspnea. Pathogens responsible for bronchiectasis
include pathogens Haemophilus influenzae, Pseudomonas aeruginosa, Streptococcus pneumoniae, Staphylococcus aureus, and nontuberculous
mycobacteria. Empirical antibiotic therapy and other drugs are used empirically in the management of bronchiectasis.Here, we discuss a case of
infectious exacerbation of bronchiectasis successfully treated with an empirical use of ceftriaxone/sulbactam/disodium edetate-1034.
Keywords: Bronchiectasis, Elores™, Ceftriaxone/sulbactam/disodium edetate-1034, Disodium edetate, Antibiotic resistance.


| PDF |

References


REFERENCES

Rabe KF. Guidelines for chronic obstructive pulmonary disease

treatment and issues of implementation. Proc Am Thorac Soc

;3(7):641-4.

Bilton D, Jones AL. Bronchiectasis: Epidemiology and causes. Eur

Respir Monogr Eur Respir Mon 2011;52:1-10.

Pasteur MC, Bilton D, Hill AT. British thoracic society bronchiectasis

non-CF guideline Group. British thoracic society guideline for non-CF

bronchiectasis. Thorax 2010;65 Suppl 1:i1-58.

Weycker D, Edelsberg J, Oster G, Tino G. Prevalence and

economic burden of bronchiectasis. Am J Respir Crit Care Med

;169:A330.

Ringshausen FC, de Roux A, Pletz MW, Hamalainen N, Welte T,

Rademacher J. Bronchiectasis-associated hospitalizations in Germany,

-2011: A population-based study of disease burden and trends.

PLoS One 2013;8(8):e71109.

Hill AT, Welham S, Reid K, Bucknall CE. British thoracic society national

bronchiectasis audit 2010 and 2011. Thorax 2012;67(10):928-30.

Bopaka RG, Khattabi WE, Janah H, Jabri H, Afif H. Bronchiectasis:

A bacteriological profile. Pan Afr Med J 2015;22:378.

Barker AF. Bronchiectasis. N Engl J Med 2002;346:1383-93.

Shah PL, Mawdsley S, Nash K, Cullinan P, Cole PJ, Wilson R.

Determinants of chronic infection with Staphylococcus aureus in

patients with bronchiectasis. Eur Respir J 1999;14:1340-4.

Bronchiectasis. In: European Lung White Book. Available from: http://

www.erswhitebook.org/chapters/bronchiectasis/. [Last accessed on

Sep 21].

Chaudhary M, Payasi A. A randomized, open-label, prospective,

multicenter phase-III clinical trial of Elores in lower respiratory tract

and urinary tract infections. J Pharm Res 2013;6:409-14.

Seitz AE, Olivier KN, Steiner CA, de Oca RM, Holland SM, Prevots DR.

Trends and burden of bronchiectasis-associated Hospitalizations in the

United States, 1993-2006. Chest 2010;138(4):944-9.

Woodhead M, Blasi F, Ewig S, Garau J, Huchon G, Ieven M, et al. Joint

taskforce of the European respiratory society and European society

for clinical microbiology and infectious diseases. Guidelines for the

management of adult lower respiratory tract infections. Clin Microbiol

Infect 2011;17(6):E1-59.

Byarugaba DK. Mechanisms of antimicrobial resistance. In: Sosa AJ,

Byarugaba DK, Amabile C, editors. Antimicrobial Resistance in

Developing Countries. Springer Science Business Media, LLC; 2009.

DOI 10.1007/978-0-387-89370-9_2.

Chaudhary M, Kumar S, Payasi A. A novel approach to combat acquired

multiple resistance in Escherichia coli by using EDTA as efflux pump

inhibitor. J Microb Biochem Technol 2012;4:126-30.

Chaudhary M, Kumar S, Payasi A. Role of CSE1034 in Escherichia coli

biofilm destruction. J Microb Biochem Technol 2013;5:54-8.

Chaudhary M, Sudaroli M, Kumar S, Krishnaraju V. Catering ESBL

resistance challenge through strategic combination of ceftriaxone,

sulbactam and ethylenediamine tetraacetic acid. Int J Drug Dev Res

;4(1):72-81.

Chaudhary M, Payasi A. Ethylenediamine tetraacetic acid: A non

antibiotic adjuvant enhancing Pseudomonas aeruginosa susceptibility.

Afr J Microbiol Res 2012;6:6799-804.

Monograph. Baddi, India: Venus Medicine Research Center.

Chaudhary M, Payasi A. Molecular characterization and in vitro

susceptibilities of β-lactamase producing Escherichia coli, Klebsiella

species, Acinetobacter baumannii, Pseudomonas aeruginosa and

Staphylococcus aureus to CSE1034 and other β-lactams. Asian Pac J

Trop Med 2014;7:S217-23.

Wedzicha JA. Oral corticosteroids for exacerbations of chronic

obstructive pulmonary disease. Thorax 2000;55:S23-7.




About this article

Title

INFECTIOUS EXACERBATION OF BRONCHIECTASIS SUCCESSFULLY TREATED WITH CEFTRIAXONE/SULBACTAM/DISODIUM EDETATE-1034 (ELORES™)

DOI

10.22159/ajpcr.2017.v10i3.15791

Date

01-03-2017

Additional Links

Manuscript Submission

Journal

Asian Journal of Pharmaceutical and Clinical Research
Vol 10 Issue 3 March 2017 Page: 3-5

Print ISSN

0974-2441

Online ISSN

2455-3891

Statistics

172 Views | 40 Downloads

Authors & Affiliations

Parag Sharma


Article Tools


Email this article (Login required)
Email the author (Login required)

Refbacks

  • There are currently no refbacks.